title: Air Medical Administration of Tranexamic Acid.
abstract: Traumatic injury is a significant cause of morbidity and mortality in the United States. Massive hemorrhage is responsible for the vast majority of deaths. Evolution in trauma treatment has resulted in major improvements to emergency care. Tranexamic acid (TXA), an antifibrinolytic agent, is synthetically derived from amino acids. The CRASH-2 study demonstrated that the early administration of TXA results in significant decreases in morbidity and mortality. Experiences by coalition forces in Southwest Asia found a substantial increase in survival of trauma patients with early TXA administration. The PAMPer trial has demonstrated the success of taking plasma to the scene of the incident by helicopter; TXA offers additional benefits when transported by the same means. Air medical utilization of TXA can take battlefield trauma care to the scene of civilian traumatic injuries and save lives.
authors.affiliation: University Health-Shreveport, Shreveport, Louisiana.
authors.forename: Brian
authors.initials: B
authors.lastname: Cornelius
mesh_terms: D017732:Air Ambulances / Q000706:statistics & numerical data*; D000933:Antifibrinolytic Agents / Q000008:administration & dosage*; D004638:Emergency Treatment; D005260:Female; D006801:Humans; D015601:Injury Severity Score; D008297:Male; D015996:Survival Rate; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome; D014947:Wounds and Injuries / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid